5 results on '"Argento, C."'
Search Results
2. Improving survival with deferiprone treatment in patients with thalassemia major: A prospective multicenter randomised clinical trial under the auspices of the Italian Society for Thalassemia and Hemoglobinopathies
- Author
-
Michele Rizzo, Crocetta Argento, Angela Vitrano, Pietro Violi, R. Malizia, Domenico Giuseppe D'Ascola, Carmelo Magnano, Aurelio Maggio, Marcello Capra, Saveria Campisi, Francesco Cantella, Francesca Valeria Commendatore, Francesco Gagliardotto, Liana Cuccia, Giovanni Giugno, Rocca Cingari, Carmelo Fidone, Maria Antonietta Romeo, Paolo Rigano, Luciano Prossomariti, Anna Meo, Paolo Cianciulli, Gaetano Roccamo, Aldo Filosa, Maria Concetta Galati, Gaetano Giuffrida, Vincenzo Caruso, Turi Lombardo, Angela Ciancio, Calogera Gerardi, Maggio, A, Vitrano, A, Capra, M, Cuccia, L, Gagliardotto, F, Filosa, A, Magnano, C, Rizzo, M, Caruso, V, Gerardi, C, Argento, C, Campisi, S, Cantella, F, Commendadore, F, D’Ascola, DG, Fidone, C, Ciancio, A, Galati, MC, Giuffrida, G, Cingari, R, Giugno, G, Lombardo, T, Prossomariti, L, Malizia, R, Meo, A, Roccamo, G, Romeo, MA, Violi, P, Cianciulli, P, and Rigano, P
- Subjects
Male ,Thalassemia ,Kaplan-Meier Estimate ,law.invention ,chemistry.chemical_compound ,Randomized controlled trial ,law ,Cause of Death ,Neoplasms ,Deferiprone ,Prospective Studies ,Child ,Cause of death ,Hazard ratio ,Hematology ,Middle Aged ,Combined Modality Therapy ,Survival Rate ,Thalassemia, survival, chelation, treatment, trial, thalassemia major ,Combination ,Splenectomy ,Molecular Medicine ,Drug Therapy, Combination ,Female ,Adult ,medicine.medical_specialty ,Adolescent ,Pyridones ,Deferoxamine ,Iron Chelating Agents ,Young Adult ,Drug Therapy ,Internal medicine ,medicine ,Humans ,Blood Transfusion ,Chelation Therapy ,Heart Failure ,Kaplan-Meiers Estimate ,Proportional Hazards Models ,beta-Thalassemia ,Molecular Biology ,Survival rate ,Survival analysis ,business.industry ,Proportional hazards model ,Cell Biology ,medicine.disease ,Surgery ,chemistry ,business - Abstract
The prognosis for thalassemia major has dramatically improved in the last two decades. However, many transfusion-dependent patients continue to develop progressive accumulation of iron. This can lead to tissue damage and eventually death, particularly from cardiac disease. Previous studies that investigated iron chelation treatments, including retrospective and prospective non-randomised clinical trials, suggested that mortality, due mainly to cardiac damage, was reduced or completely absent in patients treated with deferiprone (DFP) alone or a combined deferiprone-deferoxamine (DFP-DFO) chelation treatment. However, no survival analysis has been reported for a long-term randomised control trial. Here, we performed a multicenter, long-term, randomised control trial that compared deferoxamine (DFO) versus DFP alone, sequential DFP-DFO, or combined DFP-DFO iron chelation treatments. The trial included 265 patients with thalassemia major, with 128 (48.3%) females and 137 (51.7%) males. No deaths occurred with the DFP-alone or the combined DFP-DFO treatments. One death occurred due to graft versus host disease (GVHD) in a patient that had undergone bone marrow transplantation; this patient was censored at the time of transplant. Only one death occurred with the DFP-DFO sequential treatment in a patient that had experienced an episode of heart failure one year earlier. Ten deaths occurred with the deferoxamine treatment. The main factors that correlated with an increase in the hazard ratio for death were: cirrhosis, arrhythmia, previous episode of heart failure, diabetes, hypogonadism, and hypothyroidism. In a Cox regression model, the interaction effect of sex and age was statistically significant (p-value
- Published
- 2009
3. Bleeding Risk With Combination Intrapleural Fibrinolytic and Enzyme Therapy in Pleural Infection: An International, Multicenter, Retrospective Cohort Study.
- Author
-
Akulian J, Bedawi EO, Abbas H, Argento C, Arnold DT, Balwan A, Batra H, Uribe Becerra JP, Belanger A, Berger K, Burks AC, Chang J, Chrissian AA, DiBardino DM, Fuentes XF, Gesthalter YB, Gilbert CR, Glisinski K, Godfrey M, Gorden JA, Grosu H, Gupta M, Kheir F, Ma KC, Majid A, Maldonado F, Maskell NA, Mehta H, Mercer J, Mullon J, Nelson D, Nguyen E, Pickering EM, Puchalski J, Reddy C, Revelo AE, Roller L, Sachdeva A, Sanchez T, Sathyanarayan P, Semaan R, Senitko M, Shojaee S, Story R, Thiboutot J, Wahidi M, Wilshire CL, Yu D, Zouk A, Rahman NM, and Yarmus L
- Subjects
- Humans, Tissue Plasminogen Activator adverse effects, Fibrinolytic Agents adverse effects, Retrospective Studies, Hemorrhage chemically induced, Hemorrhage epidemiology, Enzyme Therapy, Pleural Effusion complications, Pleural Diseases complications, Communicable Diseases, Empyema, Pleural drug therapy, Empyema, Pleural epidemiology, Empyema, Pleural complications
- Abstract
Background: Combination intrapleural fibrinolytic and enzyme therapy (IET) has been established as a therapeutic option in pleural infection. Despite demonstrated efficacy, studies specifically designed and adequately powered to address complications are sparse. The safety profile, the effects of concurrent therapeutic anticoagulation, and the nature and extent of nonbleeding complications remain poorly defined., Research Question: What is the bleeding complication risk associated with IET use in pleural infection?, Study Design and Methods: This was a multicenter, retrospective observational study conducted in 24 centers across the United States and the United Kingdom. Protocolized data collection for 1,851 patients treated with at least one dose of combination IET for pleural infection between January 2012 and May 2019 was undertaken. The primary outcome was the overall incidence of pleural bleeding defined using pre hoc criteria., Results: Overall, pleural bleeding occurred in 76 of 1,833 patients (4.1%; 95% CI, 3.0%-5.0%). Using a half-dose regimen (tissue plasminogen activator, 5 mg) did not change this risk significantly (6/172 [3.5%]; P = .68). Therapeutic anticoagulation alongside IET was associated with increased bleeding rates (19/197 [9.6%]) compared with temporarily withholding anticoagulation before administration of IET (3/118 [2.6%]; P = .017). As well as systemic anticoagulation, increasing RAPID score, elevated serum urea, and platelets of < 100 × 10
9 /L were associated with a significant increase in bleeding risk. However, only RAPID score and use of systemic anticoagulation were independently predictive. Apart from pain, non-bleeding complications were rare., Interpretation: IET use in pleural infection confers a low overall bleeding risk. Increased rates of pleural bleeding are associated with concurrent use of anticoagulation but can be mitigated by withholding anticoagulation before IET. Concomitant administration of IET and therapeutic anticoagulation should be avoided. Parameters related to higher IET-related bleeding have been identified that may lead to altered risk thresholds for treatment., (Copyright © 2022 The Author(s). Published by Elsevier Inc. All rights reserved.)- Published
- 2022
- Full Text
- View/download PDF
4. Maternal body mass index associates with blastocyst euploidy and live birth rates: the tip of an iceberg?
- Author
-
Fabozzi G, Cimadomo D, Allori M, Vaiarelli A, Colamaria S, Argento C, Amendola MG, Innocenti F, Soscia D, Maggiulli R, Mazzilli R, Ubaldi N, Iussig B, Marchetti M, Rienzi L, and Ubaldi FM
- Subjects
- Adult, Female, Humans, Middle Aged, Pregnancy, Retrospective Studies, Young Adult, Abortion, Spontaneous etiology, Birth Rate, Body Mass Index, Embryo, Mammalian abnormalities, Overweight complications
- Abstract
Research Question: Does maternal preconceptional body mass index (BMI) associate with mean blastocyst euploidy rate (m-ER) per patient and live birth rate (LBR) after vitrified-warmed euploid single embryo transfer (SET)?, Design: Observational study conducted between April 2013 and March 2020 at a private IVF clinic, involving 1811 Caucasian women undergoing trophectoderm biopsy and comprehensive chromosome testing. The outcomes of 1125 first vitrified-warmed euploid SET were also analysed. Patients were clustered as normal weight (BMI 18.5-25; n = 1392 performing 859 SET), underweight (BMI <18.5; n = 160 performing 112 SET) and overweight (BMI >25; n = 259 performing 154 SET). m-ER per patient was the primary outcome. The secondary outcomes were all clinical outcomes per euploid SET. All data were adjusted for confounders through regression analyses., Results: The m-ER per patient decreases as maternal BMI increases from 17 up to 22-23 before reaching a plateau. A linear regression adjusted for maternal age confirmed this moderate association (unstandardized coefficient B: -0.6%, 95% confidence interval [CI]: -1.1 to -0.1%, P = 0.02). All clinical outcomes were similar between normal weight and underweight women. Overweight women, instead, showed higher miscarriage rate per clinical pregnancy (n = 20/75, 26.7% versus n = 67/461, 14.5%; odds ratio [OR] adjusted for blastocyst quality and day of full blastulation: 2.0, 95% CI: 1.1-3.6, P = 0.01) and lower LBR per SET (n = 55/154, 35.7% versus n = 388/859, 45.2%; OR adjusted for blastocyst quality and day of full blastulation: 0.67, 95% CI: 0.46-0.96, P = 0.03)., Conclusion: These data indicate a need for future research on more sensitive metrics to assess body fat mass and distribution, as well as on the mechanisms leading to lipotoxicity, thereby impairing embryo competence and/or endometrial receptivity. Overweight women should be informed of their higher risk for miscarriage and, whenever possible, encouraged to lose weight, especially before transfer., (Copyright © 2021 Reproductive Healthcare Ltd. Published by Elsevier Ltd. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
5. Normal serum concentrations of anti-Müllerian hormone in women with regular menstrual cycles.
- Author
-
La Marca A, Sighinolfi G, Giulini S, Traglia M, Argento C, Sala C, Masciullo C, Volpe A, and Toniolo D
- Subjects
- Adolescent, Adult, Aging, Contraceptives, Oral therapeutic use, Cross-Sectional Studies, Female, Humans, Menstrual Cycle, Middle Aged, Reference Values, White People, Anti-Mullerian Hormone blood
- Abstract
Anti-Müllerian hormone (AMH) has become the 'molecule of the moment' in the field of reproductive endocrinology. Indeed, it is valuable as a means of increasing understanding of ovarian pathophysiology and for guiding clinical management across a broad range of conditions. However, no normative values have been established for circulating AMH in healthy women. In this cross-sectional study, 277 healthy females (aged 18-50 years) were included. AMH was measured by commercial enzyme-linked immunosorbent assay. Serum AMH concentrations show a progressive decline with female ageing. The age-related changes in AMH were best fitted by a polynomial function. Mean AMH concentrations were not modified by past use of oral contraceptive and were independent of parity of women. Age-specific normative values for circulating AMH concentration were established. AMH concentrations seem to be independent of the reproductive history of the patient., (Copyright © 2010 Reproductive Healthcare Ltd. Published by Elsevier Ltd. All rights reserved.)
- Published
- 2010
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.